Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē^® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.

Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.

Respicardia, Inc. announced today that Richard L. Roudebush VA Medical Center in Indianapolis is the first center in Indiana to treat patients with the remedē^® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).

Dr. Alan Schwartz et al. evaluate the physiologic mechanisms by which transvenous phrenic nerve stimulation (TPNS) successfully treats Central Sleep Apnea (CSA) in a male patient presenting with CSA and atrial fibrillation

A pooled analysis of the pilot and pivotal studies shows transvenous phrenic nerve stimulation (TPNS) significantly improves CSA severity, sleep quality, ventricular function, and QOL regardless of HF status